RxDoctor Payments Data

Samuel Vega, MD

Adult Medicine · Pasadena, TXNPI 1477015493

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.

$2,380in general payments, 2019–2025

Across 101 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$425
  • Bayer$354
  • Lilly USA, LLC$326
  • AstraZeneca$301
  • Novartis$169
  • Exact Sciences$151
  • plus $654 from 17 others

What the payments were for

  • Food & beverage$2,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,380 in reported general payments places this provider in the 75th percentile of 98 adult medicine providers in Texas.

See all adult medicine providers in Texas

Medicare billing

Part B allowed, 2024
$163,660
Medicare patients
344
Services billed
1,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$65,089
JanuviaSitagliptin Phosphate18$24,351
TrulicityDulaglutide20$22,457
EliquisApixaban15$17,317
FarxigaDapagliflozin Propanediol13$12,450
OzempicSemaglutide11$10,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,275
Atorvastatin Calcium170$1,957
Gabapentin88$1,594
Albuterol Sulfate HfaAlbuterol Sulfate42$1,409
Rosuvastatin Calcium86$1,394
Tamsulosin Hcl92$1,310
Pantoprazole Sodium94$1,174
Losartan Potassium103$1,145
Metoprolol Succinate61$1,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$326$22,45720 claims
AstraZenecaFarxiga$301$12,45013 claims
Novo NordiskOzempic$425$10,57411 claims
GSKTrelegy Ellipta$84$8,27513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 98 adult medicine providers in Texas.

Other adult medicine in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →